SRY-box transcription factor 21 antisense divergent transcript 1: Regulatory roles and clinical significance in neoplastic conditions and Alzheimer's Disease.
Alzheimer
Biological Functions
Clinical application
Disease biomarker
LncRNA
Neoplasms
SOX21-AS1
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
08
2023
accepted:
24
09
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
epublish
Résumé
SRY-box transcription factor 21 antisense divergent transcript 1 (SOX21-AS1) is a multifaceted long non-coding RNA (lncRNA) that plays diverse roles in both neoplastic conditions and Alzheimer's disease. Its aberrant expression intricately regulates a wide spectrum of cellular processes, spanning from epithelial-mesenchymal transition (EMT), apoptosis, migration, metastasis, and stemness to drug resistance. SOX21-AS1 achieves these effects through its involvement in the competitive endogenous RNA (ceRNA) network, modulation of downstream genes, and regulation of critical pathways, including PI3K/AKT, Hippo, Wnt/β-catenin, and ERK signaling. Of significant clinical relevance, SOX21-AS1 expression has shown robust correlations with various clinical-pathological features. Moreover, it has demonstrated promising prognostic and diagnostic potential across a spectrum of tumors, as evidenced by existing literature and TCGA pan-cancer analyses. In Alzheimer's disease, SOX21-AS1 assumes a distinctive role. It influences neuronal viability, apoptosis, and oxidative stress by interacting with miR-107 and miR-132, and affecting the PI3K/AKT and Wnt signaling pathways. This comprehensive review sheds light on the functions of SOX21-AS1 and the regulated mechanisms underpinning its impact on neoplastic conditions and Alzheimer's disease. It underscores the clinical significance of SOX21-AS1 and positions it as a promising therapeutic target in both the oncological and neurodegenerative domains.
Identifiants
pubmed: 37928430
doi: 10.7150/jca.89619
pii: jcav14p3258
pmc: PMC10622988
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
3258-3274Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
Int J Biol Macromol. 2020 Dec 1;164:1294-1303
pubmed: 32698071
Genes Dis. 2022 Jun 29;10(3):901-914
pubmed: 37396533
Signal Transduct Target Ther. 2022 Jan 3;7(1):3
pubmed: 34980884
Biochim Biophys Acta. 2011 Aug;1816(1):50-6
pubmed: 21447370
Nat Rev Mol Cell Biol. 2023 Jun;24(6):430-447
pubmed: 36596869
Pathol Res Pract. 2023 Jul;247:154545
pubmed: 37244053
Biosci Rep. 2020 Mar 27;40(3):
pubmed: 32124921
Ann Med. 2006;38(3):200-11
pubmed: 16720434
Biomed Pharmacother. 2017 Dec;96:953-959
pubmed: 29217166
Int J Mol Sci. 2023 Feb 03;24(3):
pubmed: 36769373
Clin Epigenetics. 2016 Nov 26;8:129
pubmed: 27933111
Int J Oncol. 2010 Jun;36(6):1321-9
pubmed: 20428755
Biomed Pharmacother. 2021 Oct;142:111999
pubmed: 34385106
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
J Cell Physiol. 2019 Aug;234(10):17494-17504
pubmed: 30912129
J Cell Physiol. 2018 Aug;233(8):5598-5612
pubmed: 29150936
Oncogene. 2016 Aug 25;35(34):4540-8
pubmed: 26804173
Rejuvenation Res. 2022 Oct;25(5):243-252
pubmed: 36039935
Mol Med Rep. 2023 Aug;28(2):
pubmed: 37350380
Int J Mol Sci. 2013 Sep 12;14(9):18790-808
pubmed: 24036441
Mol Biol Rep. 2020 Jun;47(6):4587-4629
pubmed: 32333246
Arch Med Res. 2021 Apr;52(3):294-303
pubmed: 33341286
Biomed Pharmacother. 2023 Jun;162:114698
pubmed: 37060661
Int J Mol Sci. 2023 Aug 06;24(15):
pubmed: 37569871
Biomed Pharmacother. 2018 Aug;104:137-144
pubmed: 29772433
J Cancer. 2021 Mar 15;12(10):2921-2932
pubmed: 33854593
Neurochem Res. 2021 Sep;46(9):2376-2386
pubmed: 34146195
Biomed Pharmacother. 2023 Jul;163:114756
pubmed: 37105079
Neoplasma. 2020 Mar;67(2):333-343
pubmed: 31973536
Life Sci. 2019 Sep 15;233:116708
pubmed: 31369759
J Transl Med. 2022 Nov 5;20(1):511
pubmed: 36335356
Biotechniques. 2013 Jun;54(6):301, 303-4
pubmed: 23750541
Reprod Sci. 2021 Feb;28(2):532-540
pubmed: 33095426
Life Sci. 2023 Oct 1;330:122006
pubmed: 37544376
Biomed Pharmacother. 2021 Jul;139:111604
pubmed: 33895520
Bioengineered. 2021 Dec;12(1):6724-6737
pubmed: 34511042
Front Oncol. 2022 Jun 02;12:920926
pubmed: 35719945
Sci Rep. 2023 Jul 3;13(1):10697
pubmed: 37400520
Nature. 1997 May 8;387(6629):151-8
pubmed: 9144284
J Cell Biochem. 2020 Nov;121(11):4601-4611
pubmed: 32277517
Front Endocrinol (Lausanne). 2020 Jun 23;11:403
pubmed: 32655497
Cell Death Dis. 2020 Sep 24;11(9):797
pubmed: 32973135
Annu Rev Biochem. 2012;81:145-66
pubmed: 22663078
Mol Neurodegener. 2008 Jul 24;3:9
pubmed: 18652670
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
Cancer Manag Res. 2020 Nov 02;12:11005-11014
pubmed: 33173334
Nat Genet. 1995 Oct;11(2):204-6
pubmed: 7550351
FEBS Open Bio. 2021 Jan;11(1):251-264
pubmed: 33103351
BMC Cancer. 2008 Mar 06;8:68
pubmed: 18325103
Bioengineered. 2022 Mar;13(3):6678-6687
pubmed: 34696664
J Cancer. 2021 Feb 22;12(8):2336-2350
pubmed: 33758610
Int J Clin Exp Med. 2015 Jun 15;8(6):8599-607
pubmed: 26309511
J Transl Med. 2023 Aug 18;21(1):556
pubmed: 37596669
Cell. 1993 Nov 19;75(4):817-25
pubmed: 8242752
Cancers (Basel). 2021 Aug 05;13(16):
pubmed: 34439105
Annu Rev Cell Dev Biol. 2001;17:615-75
pubmed: 11687500
Cancer Lett. 2013 Oct 10;339(2):159-66
pubmed: 23791884
Eur J Cancer. 2013 Sep;49(13):2934-48
pubmed: 23683890
Pathol Res Pract. 2023 Sep;249:154738
pubmed: 37595448
J Cancer. 2022 Mar 21;13(6):1882-1894
pubmed: 35399723
Biosci Rep. 2019 May 17;39(5):
pubmed: 30992391
Neurotox Res. 2019 Apr;35(3):775-795
pubmed: 30707354
Front Cell Dev Biol. 2023 Jun 13;11:1164301
pubmed: 37384249
Biomed Pharmacother. 2023 Jun;162:114692
pubmed: 37058817
Nat Rev Mol Cell Biol. 2020 Oct;21(10):607-632
pubmed: 32576977
Mol Neurobiol. 2019 May;56(5):3522-3537
pubmed: 30143969
World J Surg Oncol. 2023 Jul 22;21(1):217
pubmed: 37481582
Oncotarget. 2018 Jul 3;9(51):29548-29564
pubmed: 30038703
FEBS Lett. 2016 Aug;590(16):2700-8
pubmed: 27339400
Cancer Biol Ther. 2007 Aug;6(8):1171-2
pubmed: 17726367
Cancer Res. 2010 Feb 15;70(4):1668-78
pubmed: 20124479
Front Genet. 2022 May 26;13:903117
pubmed: 35692827
Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118
pubmed: 33353982
Nat Rev Cancer. 2009 Jun;9(6):400-14
pubmed: 19440234
Nat Rev Genet. 2006 Aug;7(8):606-19
pubmed: 16847462
Cell Physiol Biochem. 2017;42(5):1857-1869
pubmed: 28873379